ProPhase Labs, Inc. (PRPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ProPhase Labs, Inc. (PRPH) Healthcare & Pipeline Overview

ProPhase Labs, Inc. focuses on the development, manufacturing, and marketing of over-the-counter healthcare products and diagnostic services, including COVID-19 testing. The company operates through its Consumer Products and Diagnostic Services segments, serving national chain drug, internet-based, and regional retailers in the United States.

What Is the Investment Thesis for PRPH?

ProPhase Labs operates in the OTC consumer healthcare products and diagnostic services market. With a market capitalization of $0.00B and a negative P/E ratio of -0.01, the company's financial performance reflects challenges. The gross margin of 191.4% indicates strong potential in product pricing and cost management, while the negative profit margin of -3872.2% suggests significant operational inefficiencies or high costs. Key growth catalysts include expanding the diagnostic services segment and introducing new consumer healthcare products. Potential risks include intense competition, regulatory changes, and the sustainability of COVID-19 testing revenue. The company's beta of -0.52 indicates lower volatility compared to the market.

Based on FMP financials and quantitative analysis

PRPH Key Highlights

Market Cap of $0.00B reflects the company's current valuation in the market.

• P/E Ratio of -0.01 indicates the company is not currently profitable.
• Gross Margin of 191.4% suggests strong potential in product pricing and cost management.
• Profit Margin of -3872.2% indicates significant operational inefficiencies or high costs.
• Beta of -0.52 suggests the stock is less volatile than the market.

Who Are PRPH's Competitors?

PRPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PRPH's Key Strengths?

Established presence in the OTC consumer healthcare market.

• Diagnostic services segment provides a growing revenue stream.
• Contract manufacturing capabilities offer diversification.
• Proprietary product formulations.

What Are PRPH's Weaknesses?

Negative profit margins indicate financial challenges.

• High dependence on COVID-19 testing revenue.
• Limited brand recognition compared to larger competitors.
• Small market capitalization.

What Could Drive PRPH Stock Higher?

Launch of new OTC consumer healthcare products targeting specific health needs.

• Expansion of diagnostic services beyond COVID-19 testing.
• Strategic partnerships to enhance market reach and product distribution.
• Leveraging contract manufacturing capabilities to attract more clients.

What Are the Key Risks for PRPH?

Financial-distress signal — its Altman Z-Score of -3.95 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Intense competition in the OTC healthcare market.
• Regulatory changes affecting diagnostic testing and OTC products.
• Decline in COVID-19 testing demand.
• Economic downturn affecting consumer spending on healthcare products.
• The company's financial performance is heavily reliant on the success of its key products and services.

What Are the Growth Opportunities for PRPH?

• Expansion of Diagnostic Services: ProPhase Labs can expand its diagnostic services beyond COVID-19 testing to include a broader range of molecular and genetic testing services. The market for genetic testing is projected to reach $25.9 billion by 2027, growing at a CAGR of 11.4% from 2020. By offering comprehensive testing solutions, ProPhase Labs can attract a wider customer base and increase revenue. Timeline: 1-3 years.
• New Consumer Healthcare Products: ProPhase Labs can develop and launch new OTC consumer healthcare products targeting specific health needs. By focusing on innovative formulations and effective marketing, ProPhase Labs can capture a larger share of the market. Timeline: 2-4 years.
• Strategic Partnerships: Forming strategic partnerships with healthcare providers, retailers, and other companies can enhance ProPhase Labs' market reach and product distribution. Collaborations can lead to new product development opportunities and access to new customer segments. Timeline: Ongoing.
• Geographic Expansion: ProPhase Labs can expand its operations beyond the United States to international markets. The global dietary supplements market is expected to reach $230.73 billion by 2027. By entering new geographic regions, ProPhase Labs can diversify its revenue streams and reduce its dependence on the US market. Timeline: 3-5 years.
• Contract Manufacturing Services: ProPhase Labs can leverage its contract manufacturing capabilities to attract more clients and increase revenue. The contract manufacturing market for pharmaceuticals is growing due to the increasing demand for outsourcing manufacturing activities. By offering high-quality manufacturing services, ProPhase Labs can establish long-term relationships with clients. Timeline: Ongoing.

What Are PRPH's Competitive Advantages?

• Established brand recognition for certain OTC products.
• Manufacturing capabilities provide control over product quality and supply chain.
• Diagnostic testing infrastructure provides a competitive edge in the healthcare market.

What Does PRPH Do?

ProPhase Labs, Inc., initially known as The Quigley Corporation, was founded in 1989 and is headquartered in Garden City, New York. The company operates in the healthcare sector, specifically focusing on the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. ProPhase Labs operates through two segments: Diagnostic Services and Consumer Products. The Consumer Products segment offers a range of OTC dietary supplements, including Legendz XL for male sexual health and Triple Edge XL, an energy and stamina booster. The Diagnostic Services segment provides contract manufacturing services, including product development, pre-commercialization, production, warehousing, and distribution. It also offers SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods, along with other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. ProPhase Labs serves national chain drug, internet-based, and various regional retailers. The company has evolved to meet the changing demands of the healthcare market, particularly with its expansion into diagnostic testing services during the COVID-19 pandemic.

What Products and Services Does PRPH Offer?

• Researches and develops over-the-counter (OTC) consumer healthcare products.
• Manufactures OTC healthcare products and dietary supplements.
• Distributes and markets its products to retailers.
• Offers Legendz XL for male sexual health.
• Provides Triple Edge XL, an energy and stamina booster.
• Provides SARS-CoV-2 (COVID-19) testing services.
• Offers respiratory pathogen panel molecular testing services.
• Provides personal genomics products and services.

How Does PRPH Make Money?

• Develops and manufactures OTC healthcare products and diagnostic tests.
• Sells products and services to national chain drug, internet-based, and regional retailers.
• Provides contract manufacturing services to other companies.

What Industry Does PRPH Operate In?

ProPhase Labs operates within the competitive healthcare industry, specifically in the drug manufacturers and diagnostic services market. The industry is characterized by stringent regulatory requirements, rapid technological advancements, and evolving consumer preferences. The market for OTC consumer healthcare products is driven by increasing health awareness and self-medication trends. The diagnostic services market, particularly for molecular testing, has seen significant growth due to the COVID-19 pandemic. ProPhase Labs competes with other specialty and generic drug manufacturers, as well as diagnostic testing service providers. The company's success depends on its ability to innovate, maintain regulatory compliance, and effectively market its products and services.

Who Are PRPH's Key Customers?

• National chain drug retailers.
• Internet-based retailers.
• Regional retailers.
• Healthcare providers (for diagnostic services).
• Other companies requiring contract manufacturing services.

Company Profile

ProPhase Labs, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Uniondale, US. The company is led by CEO Ted William Karkus. PRPH has traded publicly since 1994.

ProPhase Labs, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.95 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -24.6%, showing how much profit it generates from its asset base. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.

PRPH Valuation & Market Position

Relative to its peer group, PRPH's quantitative score of 17/100 is below the peer average of 57/100.

Wall Street analysts project ProPhase Labs, Inc. revenue of about $41.7M for fiscal 2026, with EPS near $10.40.

PRPH Financials

PRPH Latest News

No recent news available for PRPH.

PRPH Analyst Consensus

PRPH MoonshotScore

PRPH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources